MA44079B1 - Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine - Google Patents

Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Info

Publication number
MA44079B1
MA44079B1 MA44079A MA44079A MA44079B1 MA 44079 B1 MA44079 B1 MA 44079B1 MA 44079 A MA44079 A MA 44079A MA 44079 A MA44079 A MA 44079A MA 44079 B1 MA44079 B1 MA 44079B1
Authority
MA
Morocco
Prior art keywords
phenylaminopyrimidine
derivative
compositions
pharmaceutical compositions
relates
Prior art date
Application number
MA44079A
Other languages
English (en)
Other versions
MA44079A (fr
Inventor
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Durga Maheswari Parvataneni
Mitrabhanu Mohanty
Venkata Satyanarayana Appadwedula
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA44079A publication Critical patent/MA44079A/fr
Publication of MA44079B1 publication Critical patent/MA44079B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique orale contenant une quantité efficace de nrc-an-019, y compris ses sels pharmaceutiquement acceptables et ses polymorphes, par dispersion dans un système polymère dans un état final de subdivision pour améliorer la biodisponibilité orale. L'invention concerne également des procédés de préparation de ces compositions et l'utilisation de ces compositions pour le traitement de la leucémie myéloïde chronique et d'autres tumeurs, telles que le cancer de la tête et du cou, le cancer de la prostate et similaires.
MA44079A 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine MA44079B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (fr) 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Publications (2)

Publication Number Publication Date
MA44079A MA44079A (fr) 2021-04-21
MA44079B1 true MA44079B1 (fr) 2021-10-29

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44079A MA44079B1 (fr) 2015-12-18 2016-01-30 Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine

Country Status (32)

Country Link
US (1) US10383872B2 (fr)
EP (1) EP3389633B1 (fr)
JP (2) JP6896738B2 (fr)
KR (1) KR20180102584A (fr)
CN (1) CN108495620B (fr)
AU (1) AU2016373574B2 (fr)
BR (1) BR112018012458A2 (fr)
CA (1) CA3008634A1 (fr)
CL (1) CL2018001590A1 (fr)
CO (1) CO2018007112A2 (fr)
CY (1) CY1124580T1 (fr)
DK (1) DK3389633T3 (fr)
EA (1) EA036513B1 (fr)
ES (1) ES2881883T3 (fr)
GB (1) GB2564262A (fr)
GE (1) GEP20207176B (fr)
HK (1) HK1254573A1 (fr)
HR (1) HRP20211590T1 (fr)
HU (1) HUE056269T2 (fr)
IL (1) IL260085B (fr)
LT (1) LT3389633T (fr)
MA (1) MA44079B1 (fr)
MX (1) MX2018007281A (fr)
PH (1) PH12018501292A1 (fr)
PL (1) PL3389633T3 (fr)
PT (1) PT3389633T (fr)
RS (1) RS62422B1 (fr)
SG (1) SG11201805142RA (fr)
SI (1) SI3389633T1 (fr)
UA (1) UA122592C2 (fr)
WO (1) WO2017103941A1 (fr)
ZA (1) ZA201804203B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3793527A1 (fr) * 2018-05-14 2021-03-24 Capsugel Belgium NV Formes posologiques solides à chargement d'agent actif élevé
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (fr) * 2010-07-02 2012-01-05 富士化学工業株式会社 Dispersion solide de bosentan
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
WO2015095659A2 (fr) * 2013-12-20 2015-06-25 Phosphorex, Inc. Composition de dispersion solide d'indirubine

Also Published As

Publication number Publication date
GB201811142D0 (en) 2018-08-22
BR112018012458A2 (pt) 2018-12-18
EP3389633A4 (fr) 2019-08-07
EP3389633B1 (fr) 2021-07-14
US10383872B2 (en) 2019-08-20
ES2881883T3 (es) 2021-11-30
EA201891443A1 (ru) 2019-01-31
DK3389633T3 (da) 2021-08-30
PT3389633T (pt) 2021-08-05
GEP20207176B (en) 2020-11-10
JP6896738B2 (ja) 2021-06-30
JP2021059551A (ja) 2021-04-15
UA122592C2 (uk) 2020-12-10
EP3389633A1 (fr) 2018-10-24
CN108495620B (zh) 2021-09-03
CO2018007112A2 (es) 2018-07-19
SI3389633T1 (sl) 2021-11-30
PH12018501292A1 (en) 2019-02-04
GEAP201614833A (fr) 2020-06-25
AU2016373574B2 (en) 2021-10-14
CA3008634A1 (fr) 2017-06-22
JP2018538325A (ja) 2018-12-27
IL260085A (en) 2018-07-31
PL3389633T3 (pl) 2021-12-13
MA44079A (fr) 2021-04-21
SG11201805142RA (en) 2018-07-30
WO2017103941A1 (fr) 2017-06-22
ZA201804203B (en) 2020-08-26
RS62422B1 (sr) 2021-10-29
HUE056269T2 (hu) 2022-02-28
US20190015412A1 (en) 2019-01-17
MX2018007281A (es) 2018-11-29
HRP20211590T1 (hr) 2022-01-07
CN108495620A (zh) 2018-09-04
GB2564262A (en) 2019-01-09
KR20180102584A (ko) 2018-09-17
CY1124580T1 (el) 2022-07-22
LT3389633T (lt) 2021-09-10
IL260085B (en) 2021-09-30
CL2018001590A1 (es) 2018-11-30
EA036513B1 (ru) 2020-11-18
HK1254573A1 (zh) 2019-07-19
AU2016373574A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA37831A1 (fr) Dérivés d'azaindole agissant comme inhibiteur de pi3k
PH12019502562A1 (en) N-substituted indole derivatives
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
BR112021011325A2 (pt) Derivados de rapamicina
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
WO2017165822A8 (fr) Inhibiteur de type petite molécule de la translocation nucléaire du récepteur aux androgènes pour le traitement du cancer de la prostate résistant à la castration
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica